Modality
ADC
MOA
SHP2i
Target
SGLT2
Pathway
Epigenetic
Cervical CaMelanomaMDS
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
May 2021
→ Aug 2030
Phase 3Current
NCT08519547
2,340 pts·Cervical Ca
2021-05→2030-08·Not yet recruiting
2,340 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-264w awayPDUFA· Melanoma
2030-08-164.4y awayPh3 Readout· Cervical Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Not yet…
Catalysts
PDUFA
2026-04-26 · 4w away
Melanoma
Ph3 Readout
2030-08-16 · 4.4y away
Cervical Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08519547 | Phase 3 | Cervical Ca | Not yet recr... | 2340 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |